Digital Pathology Solutions for Drug Development and Diagnostics

There has been a growing body of supporting evidence in the translational research field showing the role genomic- and proteomic-based platforms in enabling more informed and potentially effective therapeutic strategies in clinical development and when appropriate transitioning to diagnostic applications. Hear from Labcorp Drug Development Sr. VP and Chief Scientific Officer, Steve Anderson, PhD, Labcorp Drug Development Lead Scientist, Carlee Hemphill, MSc and Chief Scientific Officer, PathAI, Mike Montalto, PhD, discuss the landscape of innovative tools and technology within multi-omics that can provide comprehensive clinical trial testing solution. Combination of digital pathology for IHC, gene expression profiling, digital spatial profiling for a deeper investigation of disease biology and implementation of AI-powered digital pathology into clinical trials to better identify target populations therapy selection and to support downstream diagnostic development.